JARISLOWSKY FRASER Ltd Has $140.30 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

JARISLOWSKY FRASER Ltd trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 719,874 shares of the medical research company’s stock after selling 30,382 shares during the quarter. JARISLOWSKY FRASER Ltd’s holdings in IQVIA were worth $140,301,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the 4th quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. grew its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA during the 4th quarter worth approximately $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock opened at $148.90 on Friday. The stock’s 50 day moving average price is $163.91 and its two-hundred day moving average price is $188.25. The stock has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.77 billion. During the same period last year, the company posted $2.54 earnings per share. The business’s quarterly revenue was up 2.5% on a year-over-year basis. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IQV shares. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. HSBC downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. UBS Group reduced their price target on IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $231.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.